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Abstract This study aimed to systematically review and
meta-analyze the prognostic value of complete remission sta-
tus at 18F-fluoro-2-deoxy-D-glucose positron emission to-
mography (FDG-PET) in Hodgkin lymphoma after comple-
tion of first-line therapy. A systematic literature search was
performed in the MEDLINE database for suitable original
articles. The included studies were methodologically assessed
using the Quality In Prognosis Studies tool. The proportion of
patients who developed disease relapse during follow-up,
among those patients who were in complete remission accord-
ing to FDG-PET at the completion of first-line therapy, was
calculated for each included study. Heterogeneity in disease
relapse proportions across individual studies was assessed
using the I2 statistic, with heterogeneity regarded present if
I2<50 %. Weighted summary disease relapse proportion was
calculated using either a random effects model (if I2>50) or a
fixed effects model (if I2≤50). Ten studies comprising a total
number of 1137 Hodgkin lymphoma patients with complete
remission status according to FDG-PET after completion of
first-line therapy were included. Overall methodological qual-
ity of included studies was reasonably good. The disease re-
lapse rate during follow-up among all patients with complete
remission status at end-of-treatment FDG-PET ranged from 0
to 26.7 %, with a weighted summary proportion of 7.5 %
(95 % confidence interval 3.9–13.8 %) using the random ef-
fects model (I2=88.3 %). In conclusion, although the disease
relapse rate in Hodgkin lymphoma patients who achieve an
FDG-PET-based complete remission after first-line therapy is
low from an absolute point of view, it is actually high when
considering the generally favorable outcome of Hodgkin
lymphoma.
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Introduction
Hodgkin lymphoma is a relatively rare cancer, accounting for
less than 1 % of newly diagnosed cancer cases with an annual
incidence of two to three per 100,000 in the Western world [1,
2]. Early favorable Hodgkin lymphoma is defined by stage I/II
disease without risk factors such as large mediastinal mass,
extranodal disease, elevated erythrocyte sedimentation rate, or
involvement of three or more nodal areas [3]. In contrast, pa-
tients with stage I/II disease presenting with one or more of
these risk factors are usually allocated to the early unfavorable
risk group, while patients with stage III/IV disease have ad-
vanced Hodgkin lymphoma [3]. At present, patients diagnosed
with early-stage disease mostly receive combined-modality
therapy consisting of two to four cycles of chemotherapy (usu-
ally with adriamycin, bleomycin, vinblastine, and dacarbazine
[ABVD]) followed by involved-field radiation therapy [3].
Advanced Hodgkin lymphoma is usually treated with six to
eight cycles of chemotherapy (either with ABVD or escalated
bleomycin, etoposide, adriamycin, cyclophosphamide, vincris-
tine, procarbazine, and prednisone [BEACOPP]), optionally
followed by localized radiation therapy [3].
Although more than 80 % of all Hodgkin lymphoma pa-
tients can be cured with standard first-line therapy [4], early
identification of patients who will relapse after standard ther-
apy is important to start alternative effective treatments in a
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timely manner. High-dose chemotherapy followed by autolo-
gous stem cell transplantation has become the standard thera-
py for refractory or relapsed patients and leads to long-term
cure in more than 50 % of patients [2]. Meanwhile, other
promising drugs such as the antibody drug conjugate
brentuximab vedotin are being investigated in these patients
[2, 5]. There is an active search for new prognostic biomarkers
in Hodgkin lymphoma [3]. At present, the International
Prognostic Score (IPS) is the best validated clinical risk strat-
ification index to predict the outcome of patients with newly
diagnosed advanced Hodgkin lymphoma [3, 6, 7], while pos-
itron emission tomography (PET) with the glucose analogue
18F-fluoro-2-deoxy-D-glucose (FDG) is considered as the
standard of care for remission assessment in Hodgkin lympho-
ma [8–10]. A meta-analysis on the prognostic value of end-of-
treatment FDG-PET in Hodgkin lymphoma that was per-
formed more than 8 years ago reported that FDG-PET seems
to have a good diagnostic accuracy for assessing residual
Hodgkin lymphoma at the completion of first-line treatment
[11]. However, the 15 studies on Hodgkin lymphoma that
were included in that meta-analysis had considerable hetero-
geneity and suboptimal methodologic quality and reporting
[11]. Thus, although end-of-treatment FDG-PET is widely
used in clinical practice to assess complete remission status
in Hodgkin lymphoma, compelling evidence on its prognostic
value is still lacking.
The purpose of this study was therefore to systematically
review and meta-analyze the prognostic value of complete
remission status at FDG-PET in Hodgkin lymphoma after
completion of first-line therapy.
Materials and methods
Search strategy
The MEDLINE database was searched using the PubMed
interface for original articles on the prognostic value of com-
plete remission status at FDG-PET in Hodgkin lymphoma
after completion of first-line therapy, from start date to 11
December 2014. The search strategy consisted of a combina-
tion of synonyms of the terms BFDG-PET^ and BHodgkin.^
Bibliographies of included studies were checked for suitable
references that were not retrieved by the initial MEDLINE
search.
Study selection
Original studies (either retrospective or prospective) investi-
gating the prognostic value of complete remission status at
FDG-PET in Hodgkin lymphoma after completion of first-
line therapy (with or without additional radiation therapy)
were eligible for inclusion. Initially, no language restriction
was applied. Studies lacking original patient data such as re-
view articles, management guidelines, editorials, and letters
were excluded. Studies with less than 10 Hodgkin lymphoma
patients, case reports, and conference abstracts were also ex-
cluded. Potentially eligible articles from the same authors or
institution were evaluated for duplication of data. If this was
the case, only the most recent article was included. Studies
that included patients with other malignancies or lymphoma
subtypes thanHodgkin lymphomawho could not be separated
from Hodgkin lymphoma patients, studies that included pa-
tients with disease refractory to first-line therapy, studies that
included patients who had received second-line therapy who
could not be separated from patients who had received first-
line therapy, studies that only included Hodgkin lymphoma
patients who had a residual mass at end-of-treatment comput-
ed tomography (CT), studies in which complete remission
status was not based on FDG-PET findings, studies in which
the Cheson criteria [8–10] incorporating FDG-PET were not
used, and studies from which the number of disease relapses
among patients who were in complete remission according to
end-of-treatment FDG-PET could not be extracted were ex-
cluded. At the first stage, titles and abstracts of all retrieved
studies were screened and studies not meeting the above-
mentioned inclusion criteria were excluded. At the second
stage, the full-text versions of the remaining studies were ob-
tained and evaluated using the above-mentioned inclusion and
exclusion criteria.
Study quality
The quality of included studies was critically appraised using
the Quality In Prognosis Studies (QUIPS) tool, which was
developed to assess the risk of bias in studies of prognostic
factors [12]. The QUIPS tool assesses the risk of bias in six
different domains: study participation (BDoes the study popu-
lation adequately represent the population of interest?^), study
attrition (BDo the study data available [i.e., patients not lost to
follow-up] adequately represent the study sample?^), prog-
nostic factor measurement (BIs the prognostic factor measured
in a similar way for all participants?^), outcome measurement
(BIs the outcome of interest measured in a similar way for all
participants?^), study confounding (BHave important poten-
tial confounding factors appropriately been accounted for?^),
and statistical analysis and reporting (BIs the statistical analy-
sis appropriate, and are all primary outcomes reported?^) [12].
Risk of bias in each of these six domains was scored as Blow,^
Bmoderate,^ or Bhigh^ [12].
Statistical analysis
The proportion of patients who developed disease relapse dur-
ing follow-up, among those patients who were in complete
remission according to FDG-PET at the completion of first-
2 Ann Hematol (2016) 95:1–9
line therapy, was calculated for each included study.
Heterogeneity in disease relapse proportions across individual
studies was assessed using the I2 statistic, with heterogeneity
regarded present if I2>50 % [13]. Weighted summary disease
relapse proportion was calculated using either a random ef-
fects model (if there was heterogeneity across individual stud-
ies) or a fixed effects model (if there was no heterogeneity
across individual studies). Note that patients with residual or
progressive disease according to end-of-treatment FDG-PET
were not included in this analysis, because these patients may
undergo additional treatments that influence outcome. A sim-
ilar separate analysis was done for patients who had under-
gone stand-alone FDG-PET instead of integrated FDG-PET/
CT and for patients with either early stage or advanced stage
disease, if these patient data could be extracted from the orig-
inal studies. Comprehensive Meta-Analysis Version 2.2.064




The MEDLINE search yielded 1627 articles. After reviewing
titles and abstracts, 139 potentially eligible articles remained.
After reviewing the full-text versions of these articles, 56 were
excluded because they did not allow extracting the number of
disease relapses of patients who were in complete remission
according to end-of-treatment FDG-PET, 19 were excluded
because complete remission status was not based on
FDG-PET findings in all patients, 18 were excluded
because the Cheson criteria [8–10] were not used, 12
were excluded because they only included patients with
a residual mass at end-of-treatment CT, 12 were exclud-
ed because the study did not allow separate data extrac-
tion of Hodgkin lymphoma patients from patients with
other malignancies, nine were excluded because 10 or
less patients with Hodgkin lymphoma were included,
one was excluded because it reported data that were
also used in another (larger) study, one was excluded
because it included patients with refractory disease,
and one study was excluded because it was written in
Chinese. Thus, 10 studies [14–23] with a total of 1137
patients were finally included in this systematic review and
meta-analysis. The characteristics of included studies and pa-
tients and the applied study methodology are displayed in
Tables 1 and 2.
Methodological quality assessment
The six QUIPS domains with risk of bias for each of the 10
included studies are displayed in Table 3. Overall, the
methodological quality of included studies was reasonably
good. Nevertheless, there was moderate risk of bias
for the domain of prognostic factor measurement in
six studies, because five studies [17, 19–21, 23] used
a stand-alone PET system rather than integrated PET/
CT, and one study did not report at all which PET
system was used [22]. In addition, there was moderate
risk of bias for the domain of outcome measurement in
five studies, because three studies [16, 17, 20] did not
report whether all disease relapses were confirmed by
histology and two studies [21, 22] reported that histol-
ogy was not used to confirm disease relapse in all
cases.
Prognostic performance
All included studies provided data on the number of disease
relapses that occurred during follow-up. The disease relapse
rate during follow-up among all patients with complete remis-
sion status at FDG-PET after completion of first-line therapy
ranged from 0 to 26.7 % (Table 4), with a weighted summary
proportion of 7.5 % (95 % confidence interval 3.9–13.8 %)
using the random effects model (I2=88.3 %). In patients
who had undergone stand-alone FDG-PET instead of
integrated FDG-PET/CT (three studies [17, 19, 23], the
disease relapse rate during follow-up ranged from 5.1 to
11.8 %, with a weighted summary proportion of 7.0 %
(95 % confidence interval 3.7–12.9 %) using the ran-
dom effects model (I2=60.3 %). In patients with early
stage disease, the disease relapse rate during follow-up
ranged from 1.3 to 13.8 %, with a weighted summary
proportion of 5.7 % (95 % confidence interval 2.5–
12.8 %) using the random effects model (I2=68.3 %).
In patients with advanced stage disease, the disease re-
lapse rate during follow-up ranged from 0.0 to 26.7 %,
with a weighted summary proportion of 8.6 % (95 %
confidence interval 2.4–26.1 %) using the random effects
model (I2=90.0 %).
Discussion
This systematic review and meta-analysis included 10 studies
comprising a total number of 1137 Hodgkin lymphoma pa-
tients with complete remission status according to FDG-PET
after completion of first-line therapy. Meta-analytically, ap-
proximately 7.5 % of these patients develop disease relapse
during follow-up. These results were almost similar for studies
that used stand-alone PETonly (pooled disease relapse rate of
7.0 %). Importantly, it should be realized that more than 80 %
of all Hodgkin lymphoma patients can be cured with standard
first-line therapy [4]. In light of this fact, the proportion of
Hodgkin lymphoma patients with a negative end-of-
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treatment FDG-PET scan who experience relapsed disease is
relatively considerable. Therefore, end-of-treatment FDG-
PET cannot confidently confirm cure and rule out residual
disease. In addition, the results of the present meta-analysis
show that therapeutic and prognostic studies should not only
rely on end-of-treatment FDG-PET as outcome measure.
Moreover, it also indicates the need for new prognostic
biomarkers in Hodgkin lymphoma to improve risk strat-
ification [3]. Of interest, another recently published
meta-analysis in 727 Hodgkin lymphoma patients who
had a complete remission status according to end-of-
treatment FDG-PET but with a residual anatomical mass
as determined by CT after first-line therapy reported
these patients to have a pooled disease relapse rate of
6.8 % (95 % CI 2.6–12.5 %) during follow-up [24].
Although the included studies and patients are different
between these two meta-analyses, the pooled disease
relapse rates appear to be similar, with overlapping con-
fidence intervals. These data indirectly suggest that the
presence of a residual mass is not associated with a
worse outcome in patients with negative end-of-
treatment FDG-PET results.
Some caution is warranted when interpreting the re-
sults of this systematic review and meta-analysis. First,
there was heterogeneity among the results of the includ-
ed studies. Unfortunately, there were insufficient studies
to use meta-regression to investigate the causes of this
heterogeneity. One of the most likely explanations is
that the included studies enrolled patients with varying
disease stages and IPS scores, while it is known that
early stage Hodgkin lymphoma has a lower risk of dis-
ease relapse than advanced-stage lymphoma has [3].
The use of different treatment regimes may also have
accounted for the variability in disease relapse rates
among the included studies. Second, although the over-
all methodological quality of included studies was rea-
sonably good, there was a moderate risk of bias for the
QUIPS domains prognostic factor and outcome measure-
ment in about half of included studies. The former is
due to the use of stand-alone PET systems, which are
inferior to modern integrated PET/CT systems with re-
gard to image quality and anatomic definition of foci of
increased FDG uptake.[25]. The latter is either due to
the fact that it was unclear whether disease relapses
were confirmed histologically or due to the fact that
histological proof of disease relapse was not available
in all cases.
Classical Hodgkin lymphoma is characterized by a
minority of tumor cells derived from germinal center
B-cells and a vast majority of non-malignant reactive
cells [26]. Despite the large number of non-malignant
microenvironment cells, untreated Hodgkin lymphoma
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glucose transporter type 1 in Reed-Sternberg cells may
play a crucial role for the relatively high FDG uptake in
Hodgkin lymphoma [28]. One in vitro study investigat-
ed the effect of etoposide on cell death and on glucose
uptake in a Hodgkin lymphoma cell line [29]. It was
reported that decreased glucose uptake in etoposide-
treated Hodgkin lymphoma cells seemed to be very
closely correlated with drug-induced cell death [29]. In
their experiment, apoptosis was found to occur by cu-
mulative mechanisms, i.e., by both the direct action of
etoposide and indirectly via drug-induced glucose depri-
vation [29]. False-negative results due to drug-mediated
downregulation of glucose uptake in viable Hodgkin
lymphoma cells seemed to be less of a problem in that
in vitro study [29]. These previously reported data,
along with the findings of the present systematic review
and meta-analysis, indicate that although FDG imaging
itself may intrinsically be an appropriate method to
evaluate response to chemotherapy in Hodgkin lympho-
ma patients, FDG-PET cannot exclude (microscopic) re-
sidual disease due to its limited spatial resolution.
This systematic review and meta-analysis had some limi-
tations. First, patients with residual or progressive disease ac-
cording to end-of-treatment FDG-PET were excluded, be-
cause these patients usually undergo additional treatments,
which biases outcome estimates in these patients. Therefore,
the outcome of patients with a negative versus those with a
positive end-of-treatment FDG-PET scan could not be mean-
ingfully compared in this work. Nevertheless, the German
Hodgkin Study Group (GHSG) HD15 trial (which included
711 patients with advancedHodgkin lymphoma and a residual
mass of >2.5 cm at end-of-treatment CT, and who also
underwent end-of-treatment FDG-PET) has already
shown that patients with a positive end-of-treatment
FDG-PET scan have a worse outcome than those with a neg-
ative end-of-treatment FDG-PET scan, even when additional
(radiation) therapy is given in the former group [30]. On the
other hand, false-positive FDG-PET findings are common,
and biopsy and close monitoring are required for accurate
determination of residual disease [31]. Thus, both positive
and negative end-of-treatment FDG-PET findings should be
handled carefully before making clinical decisions. Second,
the data that were provided by the individual studies that were
included in this systematic review and meta-analysis did not
allow for detailed subgroup analyses according to different
Hodgkin lymphoma subtypes, disease stages, age, IPS scores,
and applied therapy regimens, although these factors
may have an impact on patient outcome. Third, in the
majority of included studies, a complete remission was
defined according to the Cheson 2007 response criteria
[10], which consider a scan negative if FDG uptake is
equal or less intense than the mediastinal blood pool
activity in lesions larger than 2 cm and more than the
background in lesions smaller than 2 cm. However, the
new Lugano 2014 response criteria [8, 9] define com-
plete remission status as FDG uptake equal to or lower
than liver uptake with or without a residual mass at CT
of any size, a method that is more reproducible [32]. As
a result, the prognostic value of FDG-PET after first-
line treatment may be different when the new interpreta-
tion criteria are applied. Fourth, pooled disease relapse rate
among the patients with complete remission status at end-of-
treatment FDG-PETwas calculated based on variable follow-
up times that were used in the included individual studies. In
nine of 10 included studies, patients who were followed up for
less than 2 years were included, whereas most relapses typically
occur within the first 3 years [2–4]. Therefore, the calculated
pooled disease relapse rate was probably underestimated.
In conclusion, although the disease relapse rate in
Hodgkin lymphoma patients who achieve an FDG-
PET-based complete remission after first-line therapy is
low from an absolute point of view, it is actually high
when considering the generally favorable outcome of
Hodgkin lymphoma.













Hutchings et al. (2014) [14] Low Low Low Low Low Low
Picardi et al. (2014) [15] Low Low Low Low Low Low
Filippi et al. (2013) [16] Low Low Low Moderate Low Low
Markova et al. (2012) [17] Low Low Moderate Moderate Low Low
Okosun et al. (2012) [18] Low Low Low Low Low Low
Zinzani et al. (2012) [19] Low Low Moderate Low Low Low
Barnes et al. (2011) [20] Low Low Moderate Moderate Low Low
Lopci et al. (2011) [21] Low Low Moderate Moderate Low Low
Straus et al. (2011) [22] Low Low Moderate Moderate Low Low
Cerci et al. (2010) [23] Low Low Moderate Low Low Low
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